Invivyd vs Protalix BioTherapeutics
IVVD and PLX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IVVD and PLX compare
Protalix BioTherapeutics is the larger company, worth 1.5 times as much as Invivyd ($244M against $158M).
Protalix BioTherapeutics grew revenue faster over the last twelve months (30.1% versus 26.3% for Invivyd).
Protalix BioTherapeutics keeps more of each dollar of sales as profit, with a net margin of 23.5% compared with −184% at Invivyd.
Protalix BioTherapeutics scores higher on the StockData Score (16 against 9 for Invivyd), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IVVD | PLX |
|---|---|---|
| Size and price | ||
| Market cap | $158M | $244M |
| Share price | $0.538 | $3.03 |
| Change, 1 year | −69.6% | 57.0% |
| Change, 5 years | −97.9% | 206% |
| Beta (5Y) | 2.47 | 1.33 |
| Employees | 122 | 226 |
| StockData Score | ||
| Total score | 9 | 16 (better) |
| Valuation score | 3 | 4 (better) |
| Growth score | 1 | 2 (better) |
| Performance score | 0 | 4 (better) |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 13.2× |
| P/S | 2.7× (better) | 3.0× |
| P/B | 0.9× (better) | 3.4× |
| EV/EBITDA | – | 9.3× |
| P/FCF | – | 31.8× |
| FCF yield | −69.2% | 3.1% (better) |
| Fair value | $0.983 | $5.40 |
| Margin of safety | 45.3% (better) | 43.9% |
| Growth | ||
| Revenue growth (TTM) | 26.3% | 30.1% (better) |
| Revenue growth, 5Y average | – | −3.5% |
| Net income growth (TTM) | – | 202% |
| EPS growth (TTM) | – | 475% |
| Profitability | ||
| Gross margin | – | 69.2% |
| Operating margin | −193% | 28.9% (better) |
| Net margin | −184% | 23.5% (better) |
| FCF margin | −188% | 9.5% (better) |
| Return on equity | −95.9% | 31.2% (better) |
| Return on invested capital | −616% | 49.5% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 5.87 (better) | 2.94 |
| Altman Z-score | −4.74 | 5.85 (better) |
| Piotroski F-score | 5 (better) | 4 |
| Dividends and buybacks | ||
| Buyback yield | −0.24% | – |
| Shareholder yield | −0.24% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 79.0% | 17.9% |
| Held by insiders | 16.7% | 3.8% |
| Insider net buying, 12 months | −$531K | $101K (better) |
| Short interest, % of float | 14.7% | 4.5% |
Go deeper
- IVVD stock overview
- IVVD income statement
- IVVD valuation and score
- PLX stock overview
- PLX income statement
- PLX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.